INVANZ
Total Payments
$256,934
Transactions
316
Doctors
130
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $60,980 | 10 | 0 |
| 2019 | $54,627 | 34 | 23 |
| 2018 | $69,072 | 94 | 56 |
| 2017 | $72,255 | 178 | 85 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $241,083 | 38 | 93.8% |
| Travel and Lodging | $7,627 | 6 | 3.0% |
| Food and Beverage | $5,224 | 268 | 2.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,000 | 4 | 1.2% |
Payments by Type
Research
$241,083
38 transactions
General
$15,851
278 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Study For Monitoring Antimicrobial Resistance Trends | Merck Sharp & Dohme Corporation | $175,239 | 0 |
| Generic-Bacterial infection-IV-reconst IV sol | Merck Sharp & Dohme Corporation | $30,051 | 0 |
| A large, retrospective, propensity score-matched study to compare the effectiveness of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections involving Enterococcus species | Merck Sharp & Dohme Corporation | $20,302 | 0 |
| National surveillance for ST131 | Merck Sharp & Dohme Corporation | $15,492 | 0 |
Top Doctors Receiving Payments for INVANZ — Page 6
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Pediatric Infectious Diseases | San Juan, PR | $10.42 | 1 |
| , MD | Nephrology | San Juan, PR | $10.22 | 1 |
| , M.D | Internal Medicine | San Juan, PR | $9.12 | 1 |
| Alicia Alonso Rodriguez | General Practice | Bayamon, PR | $8.33 | 1 |
| , M.D | Cardiovascular Disease | San Juan, PR | $7.88 | 1 |
| , M.D | Anesthesiology | Rio Piedras, PR | $6.52 | 1 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $256,934
Product Information
- Type Drug
- Total Payments $256,934
- Total Doctors 130
- Transactions 316
About INVANZ
INVANZ is a drug associated with $256,934 in payments to 130 healthcare providers, recorded across 316 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2020. In 2020, $60,980 was paid across 10 transactions to 0 doctors.
The most common payment nature for INVANZ is "Unspecified" ($241,083, 93.8% of total).
INVANZ is associated with 4 research studies, including "Study For Monitoring Antimicrobial Resistance Trends" ($175,239).